Catheter Precision (VTAK) Net Income towards Common Stockholders (2017 - 2026)

Catheter Precision (VTAK) has reported Net Income towards Common Stockholders for 10 consecutive years, with -$2.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 49.99% year-over-year to -$2.6 million in Q2 2026; TTM through Jun 2026 was -$11.3 million, a 39.97% increase from a year earlier, with the FY2025 full-year figure at -$17.2 million, up 21.18% from the prior year.
• Net Income towards Common Stockholders was -$2.6 million for Q2 2026 at Catheter Precision, up from -$3.0 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at -$6967.0 in Q1 2022 and troughed at -$67.4 million in Q1 2023.
• A 5-year average of -$7.4 million and a median of -$3.3 million in 2025 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders jumped 99.9% in 2022 and tumbled 966887.23% in 2023, its largest moves.
• Over 5 years, Net Income towards Common Stockholders stood at -$18.4 million in 2022, then soared by 97.29% to -$499000.0 in 2023, then slumped by 1027.86% to -$5.6 million in 2024, then surged by 36.71% to -$3.6 million in 2025, then advanced by 28.27% to -$2.6 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$2.6 million (Q2 2026), -$3.0 million (Q1 2026), and -$3.6 million (Q4 2025), per Business Quant data.